This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy

Authoring team

Aficamten is a small‐molecule cardiac myosin inhibitor (CMI) developed as a chronic oral treatment for patients with hypertrophic cardiomyopathy (HCM) (1):

  • is designed to reduce the hypercontractility that underlies the pathophysiology of HCM
  • targets excessive myocardial contractility and abnormal actin-myosin cross-bridge formation characteristic of HCM

NICE state (2):

“..Aficamten can be used as an option to treat symptomatic obstructive hypertrophic cardiomyopathy in adults with a New York Heart Association (NYHA) class of 2 to 3. It can only be used:

  • as an add-on to individually optimised standard care including beta-blockers, non-dihydropyridine calcium-channel blockers or disopyramide, or
  • alone if these treatments are contraindicated..”

Reference:

  1. Lutz JD et al. Towards a Quantitative Understanding of Aficamten Clinical Pharmacology: Pharmacokinetic-Cardiodynamic Modeling to Support Safety and Efficacy. CPT Pharmacometrics Syst Pharmacol. 2026 May;15(5):e70237.
  2. NICE (July 2026). Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page